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CASE REPORT
CASE REPORT
A 40-year-old woman presented with a history of a painful left 
axillary mass that had progressively increased in size. She reported 
symptoms of night sweats and weight loss. Physical examination 
revealed a 17×13 cm left axillary nodal mass. Her left breast had the 
clinical appearance of mastitis. Abnormal laboratory studies revealed 
elevated serum uric acid (0.50 mmol/l, normal 0.15 - 0.35 mmol/l) 
and lactate dehydrogenase (1 009 U/l, normal 100 - 190 U/l) levels. 
An enzyme-linked immunosorbent assay was positive and the initial 
CD4+ count was 435 cells/μml. Microscopic examination of the lymph 
node mass confirmed a diffuse large B-cell lymphoma (DLBCL). Bone 
marrow aspiration and biopsy demonstrated no evidence of infiltration 
by lymphoma. Cerebrospinal fluid (CSF) examination was negative for 
lymphoma infiltration. Both the CSF cryptococcus Indian ink and latex 
tests were negative, but a positive Varicella zoster polymerase chain 
reaction (PCR) test was reported.
A mammogram was not feasible owing to painful ulceration of the 
breast mass. A computed tomography (CT) scan of the thorax and 
abdomen revealed a 5 cm lymphoid nodal mass in the left axilla and a 
3.4 cm left supraclavicular lymph node. A gallium scan was consistent 
with uptake in an area overlying the left breast, anterior chest wall 
and markedly enlarged left axillary lymph nodes. Normal gallium 
biodistribution was seen in the rest of the body (Fig. 1). The case was 
considered to be a stage IIbE AIDS-NHL.
CHEMOTHERAPY
The standard CHOP regimen consisting of cyclophosphamide 750 mg/
m2, doxorubicin 50 mg/m2 and vincristine 1.4 mg/m2 on day 1 and 
prednisone 60 mg/day on days 1 - 5 every 3 weeks was started. She 
completed 3 cycles without significant toxicity but then presented with 
clinical progression. The left axillary lymph node and breast mass had 
the appearance of breast cancer with erythema, oedema and nipple 
retraction. A solid mass was palpable within the breast with associated 
skin ulceration and multiple cutaneous nodules over the left infra-
clavicular region (Fig. 2). 
However, an infection with varicella zoster virus (VZV) was clinically 
apparent along dermatome T11 and 5 weeks later she reported 
Primary breast lymPhoma and 
hiV/aids
Pieter Barnardt, MB ChB, Dip Oncol
Medical Imaging and Clinical Oncology, Tygerberg Hospital, Tygerberg, W Cape
Dylan Narinesingh, MD, FC Rad Onc
Trinidad San Fernando General Hospital, Trinidad
Primary extranodal lymphoma of the breast is rare and accounts for 0.04 - 0.53% of all malignant tumours, less than 1% of non-Hodgkin’s 
lymphomas (NHLs) and 1.7% of extranodal NHLs.1 Extranodal lymphoma arises from tissue other than lymph nodes and sites that normally 
contain no lymphoid tissue. This case describes the clinical and treatment dilemma posed by extranodal presentation in an AIDS-NHL patient.
Fig. 1. Gallium-67 scans of lymphoma situated in the left breast and 
axillary lymph nodes and extending into the left anterior chest wall.
Fig. 2. Clinical manifestation of an extranodal diffuse large B-cell 
lymphoma (DLBCL) of the left breast in an HIV-positive patient. Multiple 
cutaneous nodules, ulcerative skin lesions, erythema and enlarged axillary 
lymph nodes are present.
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progressive bilateral lower limb pareses with associated weakening in 
bladder control. Magnetic resonance imaging (MRI) of the vertebral 
column showed degenerative changes with no focal spinal cord lesions. 
The patient defaulted and returned 8 weeks later reporting that the mass 
was more painful and larger with newly developed nodular cutaneous 
lesions of the left breast region. She was given a 4th cycle of CHOP 
and started concomitant antiretroviral therapy (lamivudine, stavudine 
and efavirenz). Four weeks later there was no visible change in the 
axillary and breast mass. The chemotherapeutic regimen was changed 
to second-line CMV (cyclophosphamide 750 mg/m2, methotrexate 60 
mg/m2 and vincristine 1.2 mg/m2). A follow-up review revealed overt 
clinical progression, as there was an increase in both the size of the 
breast mass and the number of cutaneous lesions. A clinical oncology 
consult offered palliative radiotherapy, as she appeared resistant to 
first- and second-line chemotherapy.
The clinical dilemma was as follows: was this (i) a systemic NHL 
with extranodal involvement of the left breast; (ii) an overlooked 
primary breast lymphoma (PBL); or (iii) a misdiagnosed primary 
breast carcinoma? Before commencement of radiotherapy histological 
examination therefore again confirmed positivity for CD45 and CD20 
lymphoma cells compatible with a DLBCL.
RADIOTHERAPY
Palliative external beam radiotherapy (EBRT) with cobalt-60, consisting 
of 2 Gy × 18 fractions (36 Gy), was completed. The clinical target volume 
was determined by CT scan (Fig. 3). This included the left axillary nodal 
mass, the immediate lymphatic drainage, the left breast, the remaining 
left anterior chest wall and the left supra-clavicular region. Treatment 
was delivered using 8 MV photons with a 1 cm daily bolus.
Before initiation of EBRT the patient started allopurinol 600 mg/d to 
prevent tumour lysis syndrome. Her CD4+ count was 312 cells/μl, and 
trimetroprim-sulfamethoxazole as Pneumocystis jiroveci prophylaxis 
was added mid-course when the CD4+ count decreased to 56 cells/μl.
DISCUSSION
NHL is the second most common AIDS-associated malignancy and the 
AIDS-defining diagnosis in an estimated 1.6 - 8% of HIV patients.2 PBL 
is rare, comprising 0.4 - 0.5% of all breast malignancies reported.3 
Secondary breast lymphoma represents approximately 0.07%.4 When 
primary and secondary lymphoma cases are considered the most 
common sub-type is DLBCL (45 - 79%).5 Systemic AIDS-NHL treatment 
should include therapy for opportunistic infections (OIs) and the 
underlying HIV and involves modifications of conventional therapy. 
There appears to be a survival advantage for patients receiving CHOP-
ART therapy, suggesting that a decrease in OIs was responsible for 
reduction in morbidity.6 Based on a 15 - 20% central nervous system 
involvement at presentation, CNS prophylaxis is considered standard 
practice in AIDS-NHL. Series with chemotherapy reported a 50% 
complete response and a median survival of 18 months. An improved 
response rate does not significantly add to survival owing to relapse 
and death from AIDS progression.7
Neurological manifestations of VZV have been described. Encephalitis 
due to VZV infection results from small-vessel vasculitis, presenting 
weeks after the original infection. An urgent MRI scan or myelography 
is required to exclude extrinsic cord compression due to bacterial 
abscess, tuberculous abscess or lymphoma. If these are excluded, CSF 
should be sent for VZV PCR.8
The clinical and radiological features of PBL and carcinoma are similar, as 
both are diseases of middle age with a median onset in the 6th decade. 
Symptoms include pain, fever, sweating and weight loss. Contralateral 
involvement can be synchronous or metachronous up to 10 years after 
the primary lesion. Pathology remains the only way to differentiate 
between these malignancies, as treatment differs radically. Wiseman 
and Liao devised criteria to categorise breast lymphoma into primary 
and secondary forms.9 There is no standard treatment for PBL, and for 
small localised tumours adequate excision followed by radiotherapy 
may be effective. For widespread tumours with axillary involvement the 
addition of chemotherapy, surgery and radiotherapy may be required. 
The literature suggests that the Ann Arbor stage and histological sub-
type are significant factors for survival.10,11 Reported 5-year survival 
rates vary from 9% to 85%. PBLs have a better outcome than primary 
breast carcinomas.12
Our patient presented with apparent systemic AIDS-NHL with extranodal 
involvement of her breast, but review of her clinical presentation and 
staging allows for reclassification as a PBL. Unfortunately she was lost 
to follow-up and attempts to contact her have failed.  Close surveillance 
should be stressed, as contralateral involvement can appear up to 10 
years after the primary lesion. The era of AIDS-related malignancies 
represents a challenge. There should be a heightened clinical suspicion 
for extranodal lymphoma in AIDS-NHL patients. 
REFERENCES
1. Sokolov T, Shimonov M, Blickstein D, Nobel M, Antebi E. Primary lymphoma of the breast: unusual 
presentation of breast cancer. Eur J Surg 2000;166:390-193.
2. Pederson C, Barton SE, Chiesi A, et al. HIV-related non-Hodgkin’s lymphoma among European AIDS-
patients. Eur J Haematol 1995;55:245-250.
3. Jeon H, Akagi T, Hoshida Y, et al. Primary Non-Hodgkin’s malignant lymphoma of the breast. Cancer 
1992;70:2451-2459.
4. Domchek SM, Hecht JL, Flemming MD, et al. Lymphomas of the breast. Cancer 2002;94:6-13.
5. Duncan VE, Reddy VB, Jhala NC, et al. Non-Hodgkin’s lymphoma of the breast: a review of 18 primary and 
secondary cases. Ann Diag Path 2006;10:144-148.
6. Ratner L, Redden D, Hamzeh F, et al. Chemotherapy for HIV-NHL in combination with HAART. J Clin Oncol 
2001;15:2171-2178.
7. Schumann D, Grunewald T, Weiss R, et al. Intensive treatment of AIDS-related non-Hodgkin’s lymphomas 
with the MACOP-B protocol. Eur J Haematol 1995;54:73-77.
8. Wilson D, Naidoo S, Bekker LG, Cotton M, Maartens G, eds. In: Handbook of HIV Medicine. Cape Town: 
Oxford University Press South Africa, 2002: chapt 19, 174-185.
9. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972;29:1705-1712.
10. Mpallas G, Simatos G, Tasidou A, et al. Primary breast lymphoma in a male patient. J Breast 2003;13:436-
438.
11. Imai T, Shiga T. Primary non-Hodgkin’s malignant lymphoma of the breast: long-term follow-up. J Breast 
2004;13:152-154.
12. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-
260.
Fig. 3. SOMA vision – virtual simulator picture for the patient with breast 
lymphoma. The clinical target volume (CTV) is outlined in red. 
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